Treatment of primary and metastatic carcinoma
AssigneeSpectrum Pharmaceuticals, Inc.
InventorsAnthony W. Tolcher, Luigi Lenaz
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of treating a chemotherapy-resistant cancer, of treating a cholangiocarcinoma, of treating a metastatic carcinoma, and of treating a transition cell urothelial carcinoma by administering a therapeutically effective amount of an endothelin B (ETB) receptor agonist and a chemotherapeutic agent to a subject afflicted with such a cancer.
Claims17
A method of treating a cholangiocarcinoma, comprising:
- administering a therapeutically effective amount of an endothelin B (ETB) receptor agonist, wherein the ETB receptor agonist is IRL-1620, and a therapeutically effective amount of chemotherapeutic agent to a subject suffering from a cholangiocarcinoma;
- wherein administration results in a reduction in the size or in the growth of the cholangiocarcinoma, thereby treating the cholangiocarinoma.
A method of treating a metastatic carcinoma, comprising administering a therapeutically effective amount of an endothelin B (ETB) receptor agonist, wherein the ETB receptor agonist is IRL-1620, and a chemotherapeutic agent to a subject suffering from a metastatic carcinoma;
- wherein administration results in a reduction in the size or in the growth of the metastatic carcinoma, thereby treating the metastatic carcinoma, wherein the metastatic carcinoma is a prostate cancer, an ovarian cancer, a breast cancer or a cholangiocarcinoma.
A method of treating a transition cell urothelial carcinoma, comprising:
- administering a therapeutically effective amount of an endothelin B (ETB) receptor agonist, wherein the ETB receptor agonist is IRL-1620, and a chemotherapeutic agent to a subject suffering from a transition cell urothelial carcinoma;
- wherein administration results in a reduction in the size or in the growth of the transition cell urothelial carcinoma, thereby treating the transition cell urothelial carcinoma.
Dependencies are inferred from the claim text.